About QuaDRAD
QuaDRAD is a company based in Sapporo (Japan) founded in 2010. QuaDRAD operates in a competitive market with competitors including Adimab, Aphios, CDI Labs, Single Cell Technology and OmniAb, among others.
- Headquarter Sapporo, Japan
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of QuaDRAD
Investors in QuaDRAD
QuaDRAD has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Mitsubishi UFJ Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital is invested in AI, energy, and various sectors.
|
Locked | Locked | Locked |
Investor details for QuaDRAD
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by QuaDRAD
Investment portfolio details for QuaDRAD
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - QuaDRAD
Detailed financials for QuaDRAD
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Quadrad Comparisons
Peer comparison for QuaDRAD
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of QuaDRAD
QuaDRAD operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Adimab, Aphios, CDI Labs, Single Cell Technology and OmniAb, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Antibodies are discovered and optimized for autoimmune and infectious diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and infectious diseases are developed.
|
|
| Locked | Locked | Locked |
Autoantibody detection and profiling products and services are provided.
|
|
| Locked | Locked | Locked |
Antibodies and mRNA are discovered from individual antibody-secreting cells.
|
|
| Locked | Locked | Locked |
Transgenic animal platforms are developed for human therapeutic antibody production.
|
Detailed competitors of QuaDRAD
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Quadrad
Complete news archive for QuaDRAD
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about QuaDRAD
QuaDRAD was founded in 2010 and raised its 1st funding round 6 years after it was founded.
QuaDRAD is headquartered in Sapporo, Japan. It is registered at Sapporo, Hokkaido, Japan.
Medicinal chemistry pharmaceutical has designed an antibody development platform called QuaDRAD system. The technology uses glycosylated peptide approach to generate monoclonal antibodies against the antigen. Produced antibodies are then screened for their specificity to the epitope ( Epitope-Defined Antibody) by using microarray technology. The positive from the screen are further tested in animal models. Glycoproteins have been known to generate antibodies specific to the sugar moieties which enables recognition of the residue irrespective of the carrier, and it has been reported that glycopeptides are presented by MHC class 1 and II, making it a potential target for therapeutics.
QuaDRAD has 1 investor. Key investors include Mitsubishi UFJ Capital.